In January 2025, AstraZeneca (NASDAQ:AZN)'s two innovative cancer therapies have been approved by the FDA; DATROWAY and combination of CALQUENCE with bendamustine and rituximab.
Datroway (datopotamab deruxtecan-dlnk) is a treatment for adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who have previously undergone endocrine-based therapy and the second is the combination of CALQUENCE (acalabrutinib) with bendamustine and rituximab to treat previously untreated mantle cell lymphoma (MCL) in adult patients who are ineligible for autologous stem cell transplantation.
The efficacy for the first therapy reached 37% reduction in the risk of compared to chemotherapy. And the second therapy demonstrated a 27% reduction in disease progression or death risk compared to standardchemoimmunotherapy. When excluding COVID-19-related deaths, the risk reduction improved to 36%.
The approval of CALQUENCE in the U.S. marks the first and only BTK inhibitor approved for first line MCL treatment and provides a critical treatment option to patients with this rare and aggressive form of non-Hodgkin lymphoma.
With these approvals, AstraZeneca works to lead advancements in treating complex and-life threatening cancers and provide patients with more treatment options to them.
The revenue of AstraZaneca has grown at a 3-year CAGR of 15.4% and Datroway marks the eighth new medicine of its targeted twenty medicines by 2030, with more revenue streams we can project higher income to be generated by AstraZaneca.
Published: January 20, 2025
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。